CTRI/2019/11/022190已完成未知
A randomized, double-blind, placebo-controlled, parallel study, to evaluate the safety and efficacy of Boswellia serrata extract 200 mg capsules of Inventia Healthcare Limited in subjects with Irritable Bowel Syndrome (IBS) - NA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects must be able to provide voluntary written informed consent and to follow protocol requirements
- •Male and female subjects aged between 18 to 65 years both inclusive
- •Subjects diagnosed with IBS as per Rome 4 criteria at the time of screening. Rome 4 Diagnostic Criteria includes
- •Recurrent abdominal pain on average at least 1 day per week in the last 3 months associated with two or more of the following
- •Related to defecation
- •Associated with a change in frequency of stool
- •Associated with a change in form appearance of stool
- •Note Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
- •Willingness to complete subject diaries and respond to study questionnaires
- •Women of childbearing potential (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the investigational product) practicing two acceptable methods of contraception
- •Acceptable methods of contraception are
- •Oral or other For Example injection patch or implant hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication
- •Intrauterine device IUD or intrauterine system IUD or IUS
- •Double barrier method of contraception condom and occlusive cap or condom and spermicidal agent
- •Male sterilization at least 6 months prior to the screening should be the sole male partner for that subject
- •Female sterilization surgical bilateral oophorectomy or tubal ligation at least 6 weeks prior to study participation
- •Total abstinence partial abstinence is not acceptable
排除标准
- •The subjects must not meet any of the following exclusion criteria:
- •1.Hypersensitivity to any of the components of Boswellia serrata extract or any of the ingredients of the formulations.
- •2.Gastrointestinal bacterial infection or parasite infestation
- •3.History of major gastrointestinal surgery
- •4.History of intolerance/ allergy to any food items
- •5.Any intervention for IBS in the period of last 4 weeks
- •6.History or presence of carcinoma colon or ulcerative colitis
- •7.Pregnant or lactating women
- •8.History or presence of any uncontrolled debilitating systemic disease (including but not limited to cardiovascular disease, hypertension, diabetes mellitus type I and II, chronic liver disease including cirrhosis, chronic kidney disease etc.)
- •9.Subjects with major surgical procedure (including periodontal) within 28 days prior to the first dose of Investigational Product.
- •10.Subjects having the following laboratory results at screening:
- •a.Hemoglobin (Hb) less than 9 g/dL
- •b.AST and ALT > 3.0 x ULN
- •c.Alkaline phosphatase > 3.0 x ULN
- •d.Serum Creatinine level > 1.25 x ULN
- •11.Subjects on anticoagulant and/or antiplatelet medications such as aspirin, clopidogrel or warfarin.
- •12.Subjects with surgical or other non-healing wounds.
- •13.Subjects with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV)
- •14.Participation in any clinical study within 30 days prior to receiving the first dose of Investigational Product.
- •15.Any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study including but not limited to psychiatric illness/social situations that would limit adherence to study requirements.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapsesMultiple sclerosisMedDRA version: 12.0Level: PTClassification code 10028245Term: <Manually entered code. Term in E.1.1>EUCTR2004-000555-42-DKSanofi-aventis US, Inc1,080
进行中（未招募）
1 期
To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2016-002976-28-ITOVARTIS PHARMA AG1,144
进行中（未招募）
1 期
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173Primary Sjögren's syndromeMedDRA version: 19.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-004616-12-DEovartis Pharma Services AG30
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000950-39-ITBAYER AG12,800
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-DEsanofi-aventis recherche et developpement805